Preparations Underway for Launch of Multinational Phase 2 Study DURHAM, N.C., May 23, 2017 – Spyryx Biosciences, Inc., a clinical-stage biopharmaceutical company developing innovative therapeutics to address severe lung diseases, shared positive data highlighting clinical safety and pharmacokinetics in healthy volunteers and the preclinical mechanism of action of SPX-101, the Company’s pipeline therapeutic treatment for […]

Company to Detail Positive Data for SPX-101 for Cystic Fibrosis DURHAM, N.C., May 16, 2017 /PRNewswire/ — Spyryx Biosciences, Inc., a clinical-stage biopharmaceutical company developing innovative therapeutics to address severe lung diseases, today announced that it will present two abstracts highlighting the safety, pharmacokinetics and mechanism of action of SPX-101, the Company’s pipeline therapeutic treatment […]

Company continues its outreach to the CF community in support of SPX-101’s Phase 2 clinical program DURHAM, N.C., May 4, 2017 – Spyryx Biosciences, Inc., a clinical-stage biopharmaceutical company developing innovative therapeutics to address severe lung disease, announced today that it will serve as the presenting sponsor of Cystic Fibrosis Canada’s 16th Broken Arrow Conference. […]